Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2013

01-10-2013 | Research Article

Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia

Authors: Eun Kyung Lee, Yu Jeung Lee

Published in: International Journal of Clinical Pharmacy | Issue 5/2013

Login to get access

Abstract

Background Dementia is a disorder that is characterized by a chronic, progressive loss of cognitive function. Anticholinergic agents that are often used with elderly patients may cause a decline in cognitive capacity; therefore, they must be used with caution. Objective We aimed to identify the prescription patterns for anticholinergic drugs in elderly outpatients with a documented diagnosis of dementia through a retrospective analysis of electronic medical records. In addition, the study aimed to identify factors influencing these prescription patterns. Setting The Kyung Hee University Hospital in Korea. Methods We studied outpatients aged ≥65 years registered with dementia between January 1, 2011 and December 31, 2011. We reviewed prescription histories, identified anticholinergic prescriptions during the study period using the anticholinergic risk scale (ARS), and examined prescription patterns in the subjects. After analysing the ARS scores for each drug and subject, we performed a statistical analysis of the factors affecting prescription patterns for anticholinergic medications in patients with ARS scores of ≥2. Main outcome measure Prescription data on anticholinergic agents. Results Of 773 elderly dementia patients, 362 patients (46.83 %) were prescribed at least one anticholinergic medication. Of the ARS 2-point anticholinergics, nortriptyline was prescribed most frequently. Among ARS 3-point anticholinergics, cyproheptadine was prescribed most frequently. An ARS score of ≥2 was given in 255 (32.98 %) patients. A multivariate logistic regression analysis of the factors associated with anticholinergic prescription patterns revealed that those patients with comorbid Parkinson’s disease received significantly fewer prescriptions (OR = 0.544; 95% CI 0.364–0.813) and those patients who were prescribed 6–10 or ≥11 medications were significantly more likely to receive anticholinergic prescriptions (OR = 3.410; 95 % CI 2.228–5.220 and OR = 4.688; 95 % CI 2.993–7.344, respectively). Conclusion Approximately 33% of the elderly dementia patients in this study were prescribed clinically significant medication regimens totaling an ARS score of ≥2. Our findings show that the total number of medications and comorbid Parkinson’s disease both influence prescription patterns for anticholinergic medications.
Literature
1.
go back to reference Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8–25.PubMedCrossRef Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8–25.PubMedCrossRef
2.
go back to reference Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
3.
go back to reference Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–97.PubMedCrossRef Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–97.PubMedCrossRef
4.
go back to reference Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease : a meta-analysis. JAMA. 2003;289:210–6.PubMedCrossRef Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease : a meta-analysis. JAMA. 2003;289:210–6.PubMedCrossRef
5.
go back to reference Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006;10:1–160. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006;10:1–160.
6.
go back to reference Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–8.PubMedCrossRef Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–8.PubMedCrossRef
8.
go back to reference American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.CrossRef American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.CrossRef
9.
go back to reference Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373–82.PubMedCrossRef Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373–82.PubMedCrossRef
10.
go back to reference Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.PubMedCrossRef Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.PubMedCrossRef
11.
go back to reference Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMed Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMed
12.
go back to reference Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–20.CrossRef Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–20.CrossRef
13.
go back to reference Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRef Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRef
14.
go back to reference Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.PubMedCrossRef Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.PubMedCrossRef
15.
go back to reference Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9:434–41.PubMedCrossRef Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9:434–41.PubMedCrossRef
16.
go back to reference Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27:987–97.PubMedCrossRef Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27:987–97.PubMedCrossRef
17.
go back to reference Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry. 2009;24:578–84.PubMedCrossRef Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry. 2009;24:578–84.PubMedCrossRef
18.
go back to reference Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198–203.PubMedCrossRef Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198–203.PubMedCrossRef
19.
go back to reference Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13:535–8.PubMed Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13:535–8.PubMed
20.
go back to reference Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Re′glat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59:143–51.PubMedCrossRef Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Re′glat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59:143–51.PubMedCrossRef
21.
go back to reference Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50:836–42.PubMedCrossRef Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50:836–42.PubMedCrossRef
22.
go back to reference Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099–105.PubMedCrossRef Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099–105.PubMedCrossRef
23.
go back to reference Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRef Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRef
24.
go back to reference Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale: results from the REPOSI study. Drugs Aging. 2013;30:103–12.PubMedCrossRef Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale: results from the REPOSI study. Drugs Aging. 2013;30:103–12.PubMedCrossRef
25.
go back to reference Karimi S, Dharia SP, Flora DS, Slattum PW. Anticholinergic burden: clinical implications for seniors and strategies for clinicians. Consult Pharm. 2012;27:564–82.PubMedCrossRef Karimi S, Dharia SP, Flora DS, Slattum PW. Anticholinergic burden: clinical implications for seniors and strategies for clinicians. Consult Pharm. 2012;27:564–82.PubMedCrossRef
26.
go back to reference Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809–17.PubMedCrossRef Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809–17.PubMedCrossRef
27.
go back to reference Lau DT, Kasper JD, Potter DE, Lyles A. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res. 2004;39:1257–76.PubMedCrossRef Lau DT, Kasper JD, Potter DE, Lyles A. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res. 2004;39:1257–76.PubMedCrossRef
Metadata
Title
Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia
Authors
Eun Kyung Lee
Yu Jeung Lee
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9793-9

Other articles of this Issue 5/2013

International Journal of Clinical Pharmacy 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.